VRSYF has dished out gains of over 1,000% on several occasions & appears ready to do it again.
Time is of the essence and it’s running out. Act fast.
Get ready to take advantage of my new trade alert. It’s a beauty.
If you haven’t yet read my main profile on the company then consider this your wakeup call. It’s the last one you are going to get so pay attention.
This is the type of stock that requires immediate action.
In July, this stock provided gains of more than 1,000% in a single day—on two seperate occasions!
My newest alert is a biotech company that makes a bold promise on its website: “Improving the quality of life at affordable prices lies at the heart of everything we do.”
VMS Rehab Systems Inc. (OTCPINK: VRSYF)
I like the sound of that.
I also believe that VRSYF’s near term setup can provide you with significant upside and two things underpin my bullishness.
Firstly, VRSYF has a very strong set of developments that pepper its profile. Two months ago the company issued revenue guidance on one of its generic drug units. According to the release VRSYF intends to spend around $2.2M per year on drug formulation and product development through 2022. The revenue payoff is projected at $38M in aggregate through 2022.
My second reason for being bullish on VRSYF is its technical setup and chart formation. The 12-month high is 2.00 and VRSYF is trading at around 0.99 presently. That’s a huge amount of upside opportunity.
RSI is just 48 and moving in the right direction. The current setup therefore offers plenty upside growth.
There have been some really big returns delivered over the last few weeks, including July 13 when the play opened at 0.09 and rallied all the way to 1.00. I’ll let you do the math on that (hold on to your chair). That way you understand why VRSYF should be taken very seriously.
And so you don’t think July 13 was a fluke, VRSYF did the same thing again on July 25. The open there was 0.05 with a 1.00 rally. Some trader somewhere is probably still counting the gains inside their trading account.
Seriously, take a really good look at VRSYF.
Check out the chart…
Here’s a link to the chart: http://www.barchart.com/interactive_charts/stocks/VRSYF
VRSYF’s (VMS Rehab Systems Inc.) is a provider of quality of life products for the home health sector and developer of generic pharmaceuticals to advance Men’s Health.
ED Drugs Market Will Reach $3.2B By 2022
The global ED drugs market is expected to reach $3.2B by 2022 according to a new report by Grand View Research Inc. Rising adoption of sedentary lifestyle and increasing prevalence of conditions causing ED such as stress, hypertension, and related medications are the key factors expected to widen the target population base for this market.
However, the market is estimated to witness decline in revenue over the forecast period. Expiration of key drugs from 2017 to 2019 is likely to curb revenue growth. On the other hand, the market is likely to open up new avenues for the generic manufacturers to capitalize on. The increasing risk of sexually transmitted diseases, narrowing of insurance coverage for ED treatment, growing threat from counterfeit drugs, and presence of social stigma in developing countries are some factors limiting penetration rates.
VMS Rehab Systems, Inc. offers guidance on BioPharmcor generic drug unit
OTTAWA, Ontario, July 6, 2016 /PRNewswire/ — In advance of European investor meetings for its Dutch based BioPharmcor BV generic drug unit, VMS Rehab Systems, Inc. (www.vmsrehabsystemsinc.com) is providing guidance on forecasted revenues and product development expenditures for the period 2016-2022.
BioPharmcor BV (www.biopharmcor.com) has recently launched a Private Placement of its voting A shares in Central Europe to be followed by a placement of SME Bonds on or before the 4th quarter 2016. It is intended that the Bonds will be floated on the Alternext Brussels Exchange. The Company will be addressing European investors at a series of investor meetings to be held throughout the summer and fall, beginning with a meeting scheduled for Monday, July 11th in Warsaw, Poland.
According to Michael S. Wexler, VMS and BioPharmcor Group Board Chairman, “We anticipate an excellent response from European investors for our BioPharmcor offerings. The selection of generic tadalafil as our initial pipeline product is strategic and will follow as early as possible on the patent expiration of the name brand reference product. Excluding any successful acquisition activity, our preliminary sales forecast through 2022 yields aggregate organic sales of Euro 34M (US $38M). We anticipate that year on year sales will grow sharply throughout the decade as generic tadalafil usage continues to rise in all markets worldwide. We must keep in mind that BioPharmcor will be offering its generic tadalafil in several dosages and is a first line treatment for both ED and Benign Prostatic Hyperplasia (BPH).”
To learn more about VRSYF please visit their website: http://vmsrehabsystemsinc.com/
Check out VRSYF now.
We have been compensated $30k cash via bank wire by a third party, ACN, LLC, to conduct investor relations advertising and marketing for VRSYF. Stellar Media’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.